Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Link: I'm a Buyer of Bristol Myers in Low $30s

Eli Lilly, Verastem and the Defenders of Shareholder Value

Obamacare vs. the Stock Market

Stocks Finish Mixed; Nasdaq Extends Rally

Stephanie Link's Can Kickers -- Notes on Bristol-Myers Squibb